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A. Wastewater composite sample collection, continued 
Immediately after collection at location K, wastewater was mixed and aliquoted in 1-L bottles 
that were frozen at -20°C. These samples were transported together on ice and processed within 
48 hours, and biological triplicates were taken from each bottle, where biological replicates refer 
to wastewater subsamples. All location K samples were processed in 
triplicate. Daily flow data throughout the study period were collected by the wastewater agency 
(Central Contra Costa Sanitary District) and used to calculate the mean flow rate. 
 
Location E samples were stored onsite at -20°C, transported to the lab on ice, returned to storage 
at -20°C, thawed at 4°C, and then processed within 48 hours. Many of the samples from this site 
went through an additional freeze-thaw during transport despite being transported on ice. For 
location E, three sample replicates were processed for each date except 5/29/20 (2), 5/31/20 (2), 
7/07/20 (2), 7/19/20 (2), 7/28/20 (2), 9/8/20 (1), and 9/14/20 (1). Daily flow data throughout the 
study period were collected by the wastewater agency (San Jose - Santa Clara Regional 
Wastewater Facility (SJSC-RWF)) and used to calculate the mean flow rate. 
 
All other samples (locations S, A, N, and Q) were collected in 1-L bottles transported on ice 
within 48 hours of collection and then frozen at -80°C until processing. For location S, no 
samples had replication except 6/30 which was processed in triplicate. For location A, samples 
were processed in duplicate from 5/28/20 to 7/28/20 and with only one replicate from 8/4/20 to 
9/9/20. For location N, no samples had biological replication. East Bay Municipal Utility District 
provided average sewershed flow rates for locations A, N, and S. 
 
For location Q, no samples had replication except 7/1 which was processed in biological duplicate. 
For Central Marin Sanitation Agency only data from 6/1/20 to 7/13/20 were used in calculation of 
the average flow due to flow meter malfunction after this point. 
 
B. Wastewater sample processing via the 4S method, continued   
Briefly, sodium chloride was added to 40-50 mL of wastewater to a final concentration of 4 M, 
Ethylenediaminetetraacetic acid was added to a final concentration of 1 mM, and the solution 
was buffered using 10mM tris(hydroxymethyl)aminomethane to pH 7.2. Samples were heated to 
70°C for 45 minutes and prefiltered with a 5-μm PVDF filter using syringe filtration. The filtrate 
was mixed with 40 mL of 70% ethanol and vacuum filtered through a silica column (Zymo III-
P), and the column was washed using 5 mL of wash buffer 1 and 10 mL of wash buffer 2. 
Genetic material was eluted from the column by adding 200 μL ZymoPURE elution buffer and 
heating the column with elution buffer to 50°C for 10 minutes, then centrifuging the column to 
collect the flowthrough. The eluate was stored in multiple tubes to minimize freeze-thaw at -
80°C until qPCR.  
 
Each extraction batch contained a negative control of 40 mL of phosphate buffered saline (PBS) 




solution of 1.33x109 gene copies/μL) and 50 μL of a surrogate virus lysis/extraction control from 
the same bottle of Bovilis Coronavirus Calf Vaccine (Merck Animal Health, Merck & Co. Inc., 
Kenilworth, NJ, USA) resuspended in 20 mL of PBS to monitor recovery with and without lysis 
across batches. Four representative samples were chosen from each location to assess SOC and 
BCoV recovery along with the batch PBS control, and Cts remained relatively consistent for 
SOC and varied considerably for BcoV. However, we saw no signs that an extraction procedure 
failed and considered all samples to pass this quality control screen.  
 
C. RT-qPCR plate setup and controls, continued 
To minimize qPCR contamination, sample processing and RT-qPCR plate assembly were 
performed in separate laboratories. Primers and probes were purchased as custom DNA oligos 
(Integrated DNA Technologies), except for the N1 assay (2019-nCoV CDC RUO Kit) and the 
Xeno assay (VetMAX™ Xeno™ Internal Positive Control - VIC™ Assay, ThermoFisher 
Scientific). Standard curves consisted of 10-fold serial dilutions of RNA standard from the same 
production batch of either synthetic RNA (Control 2- 102024, Twist Bioscience, San Francisco, 
CA) for the N1 assay, RNA from custom Ultramer RNA Oligonucleotides (Integrated DNA 
Technologies) for BCoV and PMMoV, geneBlocks DNA (Integrated DNA Technologies) for 
crAssphage, or RNA in-vitro transcribed from geneBlocks (Integrated DNA Technologies) with 
a HiScribe T7 Quick High Yield RNA Synthesis kit (New England Biolabs) for the Bacteroides, 
SOC, and 18S assays.  
 
A subset of samples were run with no reverse transcription (No-RT) controls for Bacteroides 
rRNA and 18S rRNA assays to assess the relative contributions of RNA and DNA template to 
the target signal because both are expected to be present in samples. No-RT controls were 
conducted by heat-inactivating the reverse transcription enzyme in the Taqman Fast Virus One-
Step Mastermix at 95°C for 5 minutes as per manufacturer’s instructions before continuing with 
qPCR. Results were compared to the same samples with the RT step included. RNA was found 
to be multiple orders of magnitude greater than DNA in the samples tested, and results are given 
in Table S7. RNA and DNA yield were quantified via Qubit and found to be proportional 
(Figure S1). 
D. qPCR data processing  
Raw Cq values were imported into a custom pipeline in python (v3.6.9) with key modules 
including Pandas (v1.1.5) and NumPy (v1.19.5). First, raw Cq values that did not amplify or that 
amplified below the limit of detection were substituted with the Cq value corresponding to half 
the limit of detection (for N1) or half the bottom of the master standard curve (for all other 
assays) (Table S5) so that unamplified values could be considered during outlier analysis. The 
N1 limit of detection (LoD) was calculated by analyzing all the RNA standard curves from the 
study as well as four additional triplicate standard curves that extended down to 0.3 gc/μL 
(Table S8). The N1 LoD was set at 5 gc/rxn, at which point 67% of technical replicates were 
positive (Table S8). The number of true unamplified values was also determined prior to 
substitution. 24 samples were deemed below the N1 limit of detection (Table S12) and were set 
to half the detection limit. For normalization purposes only, all samples that were below the 




within each location instead of the measured value, such that when N1 values below the 
detection limit were normalized, all values were equal. Next, outlier testing was performed using 
a two-sided Grubbs Test (alpha= 0.05; scikit-learn v0.22.post1). Raw Cq values that did not pass 
scikit-learn Grubbs test were removed from further analysis. Next, Cq values were combined by 
calculating the average of the remaining values. Finally, the individual standard curve 
information was determined (Table S4) for validation after outlier assessment, but Cq values 
were converted to quantities (gene copies per reaction) using the master standard curves (Table 
S5). Individual standard curve efficiencies ranged from 83.2% to 97.8%, and R2 ranged from 
0.974 to 0.999 (Table S4). NTCs only amplified for the SOC assay and they amplified far 
outside the range of the standard curve (Cq of the NTCs= 38 and Cq of the bottom of the 
standard curve = 29; Tables S4 and S5). qPCR quantities were converted to gene copies per mL 
using the weight-based volume of the wastewater samples and the elution volume after the 4S 
extraction. For samples with biological replicates (Table 1), the geometric mean and standard 
deviation of the biological replicates were calculated (SciPy v1.4.1) and used to plot points and 
error bars respectively.  
 
E. Clinical testing and population data, continued 
For daily new cases from locations S, K, A, and N, values below 11 new cases per day were masked 
by public health departments to maintain confidentiality of the contributing population and 
substituted at 5.5 cases for further analysis (Figures 2, 4 and S12). For Location S, daily new case 
data (masked) and seven day moving averages were provided (unmasked because all values were 
>11). For location K, daily new case data (masked) were provided, and seven day moving averages 
of daily new cases were then calculated. Due to the low number of cases in locations A and N, 
most of the daily new case data were masked and are not shown. For location A, seven day moving 
averages (masked) were provided. For location N, fourteen day moving averages (masked) were 
provided. These moving averages of new COVID-19 cases per day were divided by the sewershed 
population (daily per capita cases) (Table 1). Population data were provided by East Bay 
Municipal Utility District for locations S, A, and N. Population data for location K was provided 
by the Contra Costa County Public Health Department. 
 
For San Quentin Prison (location Q), COVID-19 clinical data were obtained from the California 
Department of Corrections and Rehabilitation open data portal (1) (Table 1). These data included 
TotalConfirmed, defined as “the cumulative number of patients with a positive COVID-19 result,” 
which was divided by population to estimate new cases reported on each day. Population and 
prison capacity data were found in population reports (2). No data were masked by the California 
Department of Corrections and Rehabilitation for location Q, but instances of zero cases were 








Supplemental Figures and Tables 
 
Table S1: Physicochemical wastewater parameters for each sampling location. Cells contain 
"Not available" when parameters were not measured by the corresponding utility. For location Q, 
the flow meter malfunctioned midway through the study, and data are only reported from before 
that date. Only mean flow rates, not daily, were available for locations S, N, and A.  
Location 



















cov 2% 8% 5% 12% 
n 122 118 18 65 
S, N, A 74.5, 71.9, 72.4 


















cov 4% 33% 58% 
n 43 14 13 
E 66.6 
mean 100 289 590 275 
Not 
available 
cov 4% 7% 8% 10% 






























1x 1x 1x 1x 1x 1x 1x 
Primer F 0.5 0.4 0.9 0.5 0.5 0.5 0.5 
Primer R 0.5 0.4 0.9 0.5 0.5 0.5 0.5 
Probe 0.125 0.2 0.25 0.125 0.125 0.125 0.125 
Xeno Assay Proprietary 
(0.8 
μL/rxn) 
- - - - - - 
Xeno RNA 50 cp/μL - - - - - - 
 
 
Table S3: RT-qPCR thermocycling conditions for all assays 
 






UNG incubation 25 2:00 
RT step 50 15:00 















Table S4: qPCR assay information for the SARS-CoV-2 nucleocapsid N gene (N1), the bovine 
coronavirus transmembrane protein gene (BCoV), the pepper mild mottle virus coat protein gene 














Forward primer GACCCCAAAATCAGCGAAAT  
Reverse primer TCTGGTTACTGCCAGTTGAATCTG 












Forward primer Proprietary 





Forward primer GAGTGGTTTGACCTTAACGTTTGA 
Reverse primer TTGTCGGTTGCAATGCAAGT 
Probe FAM-CCTACCGAAGCAAATG-ZEN/IBFQ 
Amplicon 






Forward primer CTGGAAGTTGGTGGAGTT 
Reverse primer ATTATCGGCCTAACATACATC 













Forward primer GGTTCCTTTGGTCGCTCGCT 
Reverse primer GGGCTGACCGGGTTGGTTTT 
















































Forward primer CCACCAAAGTGGGCGATAAA 
Reverse primer GGTGCCATTCGCCTCAATAA 
Probe FAM/TGGCGGTGAGGAAGTTTGGAAAGA/ZEN/IBFQ 
Amplicon 








Table S5: All N1 assay RT-qPCR plate-specific standard curves after outlier assessment 











87 6 -3.8 40.31 0.9928 0.832 negative 
88 7 -3.4 39.21 0.9989 0.967 negative 
92 7 -3.56 39.69 0.9921 0.91 negative 
93 7 -3.42 40.47 0.9839 0.962 negative 
94 7 -3.44 40.6 0.9968 0.954 negative 
95 7 -3.42 38.91 0.9976 0.962 negative 
96 7 -3.46 39.28 0.9992 0.945 negative 
99 7 -3.54 40.09 0.9954 0.915 negative 
100 7 -3.51 39.56 0.9944 0.927 negative 
101 7 -3.57 40.49 0.9964 0.905 negative 
102 7 -3.38 38.79 0.9919 0.978 negative 
127 7 -3.65 40.35 0.993 0.879 negative 
 
 
Table S6: Master standard curve parameters (calculated after outlier assessment) and the values 













N1 -3.48 39.78 2.5, 38.39 5, 37.35 1E5, 22.4 0.94 0.986 
SOC -3.52 42.02 5000, 29.01 10000, 27.95 1E10, 6.85 0.92 0.997 
BCoV -3.83 47.27 50, 40.76 100, 39.61 1E8, 16.63 0.82 0.996 
PMMo
V -3.50 43.65 50, 37.71 100, 36.66 1E8, 15.67 0.93 0.995 
crAss- 
phage -3.56 43.85 500, 34.24 1000, 33.17 1E9, 11.81 0.91 0.996 
Bacter- 
oides -3.65 43.68 50, 37.47 100, 36.37 2E8, 13.36 0.88 0.985 





Table S7: Subset of samples tested with the reverse transcription step (RT) and without (no-RT 
controls) for the 18S and Bacteroides assays. Including the RT step should quantify both RNA 
and DNA, while the no-RT controls should only quantify DNA. RNA was orders of magnitude 










(RT / no-RT) 
18S 
K_K_INF_061220_3 1.00E+05 6.90E+02 1.45E+02 
K_K_INF_071020_3 2.00E+04 2.60E+02 7.69E+01 
K_K_INF_080720_2 2.80E+05 8.50E+02 3.29E+02 
K_K_INF_090420_2 1.10E+05 3.30E+02 3.33E+02 
Bacteroides 
K_K_INF_061220_2 5.60E+06 5.10E+03 1.10E+03 
K_K_INF_071020_2 2.10E+06 1.60E+03 1.31E+03 
K_K_INF_080720_2 3.00E+06 2.70E+04 1.11E+02 










Figure S1: RNA yield and DNA yield from extracted wastewater samples using the 4S 



























Table S8: Evidence for the qPCR limit of detection for the N1 assay which was chosen as 5 gene 
copies per reaction. This table includes all N1 standard curves run throughout the study and four 
additional extended standard curves with quantities below 5 gene copies per reaction. All 












0.312 0.08 12 
0.625 0.08 12 
1.25 0.25 12 
2.5 0.50 12 
5 0.67 54 
10 0.90 51 
20 0.98 54 
100 0.98 54 
1000 1 54 
10000 1 54 












Table S9: Inhibition testing for samples with Xeno dCt>2 relative to baseline in the pre-screen 





















dCt] – [Actual 
dCt] 
























1* - - 100% - - - - - 
2.6 
1.62 
2 - - 100% - - - - - 1.38 
5 - - 100% - - - - - 0.76 
10 - - 100% - - - - - 0.87 
A 
09/09/20 
1 5.32 36.85 0% 0.00 0.00 - - yes 
2.00 
2.58 
2 12.87 36.79 33% 0.58 0.42 -0.06 1.06 yes 1.77 
5 26.34 36.96 33% 0.75 1.55 0.17 1.13 yes 0.87 




1* 6.89 35.57 0% 0.00 0.00 - - no 2.79 
2 6.40 36.62 0% 1.05 -0.05 1.05 0.05 no 2.16 
4 10.73 37.10 0% 1.53 0.47 0.48 0.82 no 1.63 
8 19.54 37.29 0% 1.72 1.28 0.19 0.81 - 0.42 
N 
08/11/20 
1 32.87 33.89 0% 0.00 0.00 - - yes 
3.8 
1.52 
2* 111.73 33.18 0% -0.71 1.71 -0.71 1.71 no 1.98 
5 71.60 35.17 0% 1.28 1.02 1.99 -0.69 no 0.47 
10 47.18 36.99 33% 3.10 0.20 1.82 -0.82 - 0.73 
N 
09/01/20 
1 5.67 37.02 0% 0.00 0.00 - - yes 
2.1 
1.64 
2* 16.51 36.25 0% -0.77 1.77 -0.77 1.77 - 0.91 
5 - - 66% - - - - - 0.85 
10 - - 100% - - - - - 0.55 
S 
06/02/20 
1* 26.29 34.53 0% 0.00 0.00 - - no 
3.4 
2.90 
2 32.45 35.26 33% 0.72 0.28 0.72 0.28 no 1.89 
5 38.63 36.34 33% 1.81 0.49 1.08 0.22 - 0.52 






1* 15.01 35.57 0% 0.00 0.00 - - no 
2.8 
0.49 
2 31.46 35.78 0% 0.21 0.79 0.21 0.79 no 0.34 
5 18.23 37.42 33% 1.85 0.45 1.63 -0.33 - 0.43 
10 - - 66% - - - - - 0.53 
S 
07/14/20 
1 42.68 33.56 0% 0.00 0.00 - - no 
3.1 
1.50 
2 46.44 34.47 0% 0.91 0.09 0.91 0.09 no 1.04 
5 43.04 35.98 0% 2.42 -0.12 1.51 -0.21 no 0.88 




1* 63.43 33.14 0% 0.00 0.00 - - no 2.20 
2 70.92 34.01 0% 0.87 0.13 0.87 0.13 no 1.46 
5 91.68 35.59 0% 2.45 -0.15 1.58 -0.28 no 1.01 
10 105.94 35.89 0% 2.75 0.55 0.30 0.70 - 0.55 
E 
06/07/20 
1* - - 100% - - - - - 
2.02 
1.12 
2 - - 100% - - - - - 0.91 
5 - - 100% - - - - - 0.86 
10 - - 100% - - - - - 0.71 
E 
09/08/20 
1 4.59 37.95 0% 0.00 0.00 - - yes 
2.2 
0.88 
2* 20.04 37.02 0% -0.92 1.92 -0.92 1.92 - 0.85 
5 - - 66% - - - - - 0.31 
10 - - 100% - - - - - 0.54 
E 
09/14/20 
1* 7.16 37.27 33% 0.00 0.00  - no 
3.7 
2.58 
2 11.16 37.75 33% 0.48 0.52 0.48 0.52 - 1.10 
5 - - 50% - - - - - 0.76 








Figure S2: Lowess bandwidth parameter selection process for Location K  
(A) Residual plots for Lowess bandwidth parameter (α; column labels) determination for 
location K where the bandwidth parameter increases from inclusion of 1 data point (far left) to 
inclusion of all data points (far right) in each local regression for unnormalized N1 (top) and 
crAssphage-normalized N1 (bottom). The value of α that minimized the residual was selected 
(red boxes). (B) Visualization of how bandwidth parameter affected the Lowess trendline for 







Figure S3: Lowess bandwidth parameter selection process for Location S  
(A) Residual plots for Lowess bandwidth parameter (α; column labels) determination for 
location S where the bandwidth parameter increases from inclusion of 1 data point (far left) to 
inclusion of all data points (far right) in each local regression for unnormalized N1 (top) and 
crAssphage-normalized N1 (bottom). The value of α that minimized the residual was selected 
(red boxes). (B) Visualization of how bandwidth parameter affected the Lowess trendline for 
location S. (C) The Lowess residual of two points for crAssphage-normalized N1 obscured 







Figure S4: Lowess bandwidth parameter selection process for Location Q  
(A) Residual plots for Lowess bandwidth parameter (α; column labels) determination for 
location Q where the bandwidth parameter increases from inclusion of 1 data point (far left) to 
inclusion of all data points (far right) in each local regression for unnormalized N1 (top) and 
crAssphage-normalized N1 (bottom). The value of α that minimized the residual was selected 
(red boxes). (B) Visualization of how bandwidth parameter affected the Lowess trendline for 






Figure S5: Lowess bandwidth parameter selection process for Location A  
(A) Residual plots for Lowess bandwidth parameter (α; column labels) determination for 
location A where the bandwidth parameter increases from inclusion of 1 data point (far left) to 
inclusion of all data points (far right) in each local regression for unnormalized N1 (top) and 
crAssphage-normalized N1 (bottom). The value of α that minimized the residual was selected 








Figure S6: heatmap visualization of most optimal Lowess trendlines for SARS-CoV-2 N1 signal 










Figure S7: heatmap visualization of seven day moving average of COVID-19 daily per capita 







Figure S8: 18S rRNA flow-scaled values across K, E, and Q sampling locations with geometric 
coefficients of variation shown above the boxes. Samples that did not amplify or amplified 
below the detection limit were assigned a value half that of the assay detection limit. Because of 
the inconsistent detection and high variability in quantified samples, 18S was not measured in 









Table S10: Summary statistics of the normalization biomarkers tested in this study juxtaposed 
with ranges in literature values in raw wastewater. CrAssphage and PMMoV concentrations were 
consistent with past reported values in the literature, but to our knowledge, no prior raw wastewater 
values for Bacteroides rRNA (HF183) and 18S rRNA have been reported in the literature, although 
Cqs have been documented in raw wastewater and concentrations have been documented in other 
water types. We also measured HF183 rDNA (no RT step) in four samples and found 
concentrations to be 2.1-3.1 log lower than RNA (Table S7). 
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Figure S9. This figure illustrates the variability in the concentrations of normalization 
biomarkers across locations E, K, Q, A, N, and S. All biological replicates processed from all 
locations are included. Based on geometric coefficients of variation (shown above sample 
boxes), crAssphage and PMMoV display less variation across all the points in the study than do 
18S and Bacteroides. Additionally, target concentrations in the extraction negative controls are 
displayed for comparison. When samples or negative controls were undetected via qPCR, the 
value is plotted as half of the limit of detection for the assay. No amplification of PMMoV or 
crAssphage occurred in extraction negative controls. Three out of four negative extraction 
controls amplified above the detection limit for the Bacteroides assay, but the concentrations are 
significantly different from the sample concentrations. Three of the four extraction negative 
controls were quantifiable via the 18S rRNA assay, and the concentrations of the samples and 













Table S11: Unnormalized and normalized N1 correlations to clinical case data assessed via 
Kendall’s tau-b. Datasets include locations K, S, N, A, and Q.  
 All data Without BLoD 
Correlation to 
case data 
p value n Correlation to 
case data 
p value n 
Unnormalized 
N1 
0.43 1.85E-07 72 0.42 2.1E-05 49 
N1 / crAssphage 0.38 2.48E-06 72 0.30 2.8E-03 49 
N1 / PMMoV 0.18 3.14E-02 68 0.04 6.6E-01 47 
N1 / Bacteroides 0.35 1.70E-05 72 0.31 1.3E-03 51 
 
 
Table S12: By location, total number of biological replicates and detectable portion compared to 
the percent below the N1 limit of detection 
Location 
Total number of biological 
replicates 
Number of detectable 
biological replicates 
Percent of biological replicates  
below the limit of detection 
A 17 10 41.2 
K 39 32 17.9 
N 18 14 22.2 
Q 11 5 54.5 
S 22 22 0 






Figure S10: Kendall’s Tau-b by location for comparisons between wastewater SARS-CoV-2 N1 
signal (associated with the sample collection date) and COVID-19 cases (associated with the 
result date) both with and without samples below the N1 limit of detection (BLoD) included 
(column facets). Wastewater SARS-CoV-2 data (row facets; unnormalized N1 (gc/mL) and 
crAssphage-normalized N1 (unitless)) were compared to the seven-day moving average of 
geocoded COVID-19 new cases. The analysis was completed with wastewater date aligned with 
clinical date (no lead) as well as with one- and two-week lead times (wastewater leads clinical 
testing data by one or two weeks). Significance is indicated as <0.05 . , <0.01 *, and <0.001**. 











Figure S11: Comparison of 
geocoded COVID-19 clinical 
testing results (top) to wastewater 
SARS-CoV-2 N1 signal (middle) 
and crAssphage-normalized signal 
(bottom) at location K from June 
to September 2020. COVID-19 
clinical testing results are the 
seven-day moving averages of 
daily per capita cases with data 
aligned by episode date (yellow 
line), result date (green line), or 
specimen collection date (blue 
line), with semi-transparency to 
visualize overlapping sections. 
Wastewater SARS-CoV-2 N1 
signal is aligned by specimen 
collection date (lines are the most 




























Figure S12: For locations serving more than 80,000 people: (top) SARS-CoV-2 N1 signal in 
wastewater, where symbols indicate the amount of technical replicates that amplified during 
qPCR, horizontal dashed line indicates the limit of detection, and solid lines represent the most 
optimal Lowess trendline (Figures S2-5). (middle) SARS-CoV-2 N1 signal normalized to 
crAssphage signal in wastewater, where symbols indicate the amount of technical replicates that 
amplified during qPCR, horizontal dashed line indicates the limit of detection for N1 divided by 
the upper quartile for crAssphage for each location, and solid lines represent the most optimal 
Lowess trendlines (Figures S2-5). (bottom) Daily COVID-19 clinical testing results from 
people within each sewershed normalized to the population in each sewershed, where symbols 
are plotted at the daily new cases per 1000 people per day, the trendline represents the seven-day 







Figure S13: (A) The percent of amplified technical replicates for each value of the moving average 
of daily per capita cases (x-axis). Each biological replicate had three technical replicates, so the 
horizontal, dashed lines at 0%, 33%, 66%, and 100% show the range of values associated with 
each biological replicate that was associated with a unique x value. One or more biological 
replicates were associated with each moving average case value. The solid vertical line represents 
the estimated WBE clinical detection limit determined without masked data (2.4 cases in 100,000 
people; Figure 6). (B) The cumulative percentage of amplified wastewater technical replicates 
was calculated by ranking the moving averages of daily per capita cases (including masked clinical 
case values; x-axis) from highest to lowest and calculating the fraction of qPCR replicates that 
amplified cumulatively (y-axis) for each value of x (same methodology as in Figure 6). In both 
plots, the dashed line represents the daily new cases per capita value above which 95% of 
wastewater technical replicates amplified (including masked values; 2.2 cases in 100,000 people), 










Figure S14: Kendall’s Tau-b at location K for comparisons between wastewater SARS-CoV-2 
N1 signal (associated with the sample collection date) and COVID-19 new cases (date 
association varies as indicated by color: episode date, specimen collection date, and result date) 
both with and without samples below the N1 limit of detection (BLoD) included (column facets). 
Wastewater SARS-CoV-2 data (row facets; unnormalized N1 (gc/mL) and crAssphage-
normalized N1 (unitless)) were compared to the seven-day moving average of geocoded 
COVID-19 new cases. The analysis was completed with wastewater date aligned with clinical 
date (no lead) as well as with one- and two-week lead times (wastewater leads clinical testing 
data by one or two weeks). Significance is indicated as <0.05 . , <0.01 *, and <0.001**. Result 








Figure S15: COVID-19 tests administered per 
capita (%) during the sampling period for two 
locations: K and Q, where dashed lines are 
plotted at the mean percentage of the population 
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